- GlaxoSmithKline said Friday that the European Commission and Japanese Ministry of Health, Labour and Welfare approved Shingrix for the prevention of shingles and post-herpetic neuralgia in adults aged 50 years or older.

The approval of Shingrix follows a comprehensive Phase III clinical trial program evaluating its efficacy, safety and immunogenicity in more than 38,000 people.

Dr. Thomas Breuer, Senior Vice President and Chief Medical Officer of GSK Vaccines said: 'The approvals of Shingrix in Europe and Japan are recognition of the significant scientific advance this vaccine represents. It has shown over 90% efficacy across all age groups studied for the prevention of shingles, a painful and potentially serious disease that affects around one in three people.'

Story provided by